Medidata Solutions Inc. (NASDAQ:MDSO) Receives $55.25 Consensus Price Target from Analysts
Medidata Solutions Inc. (NASDAQ:MDSO) has been given an average recommendation of “Buy” by the thirteen research firms that are currently covering the firm. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $55.25.
MDSO has been the topic of a number of recent analyst reports. Wells Fargo & Co. lowered Medidata Solutions from an “outperform” rating to a “market perform” rating in a research note on Thursday, July 21st. Needham & Company LLC initiated coverage on Medidata Solutions in a research note on Monday, July 11th. They issued a “buy” rating and a $55.00 target price on the stock. Morgan Stanley reiterated a “buy” rating and issued a $61.00 target price on shares of Medidata Solutions in a research note on Thursday, August 25th. TheStreet upgraded Medidata Solutions from a “hold” rating to a “buy” rating in a research note on Thursday, August 25th. Finally, KeyCorp reiterated a “buy” rating on shares of Medidata Solutions in a research note on Thursday, July 7th.
Shares of Medidata Solutions (NASDAQ:MDSO) opened at 55.76 on Thursday. Medidata Solutions has a 12 month low of $30.22 and a 12 month high of $56.76. The firm’s 50-day moving average is $54.69 and its 200 day moving average is $47.27. The company has a market capitalization of $3.10 billion, a price-to-earnings ratio of 143.34 and a beta of 1.21.
Medidata Solutions (NASDAQ:MDSO) last released its earnings results on Wednesday, July 20th. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. Medidata Solutions had a return on equity of 10.32% and a net margin of 5.29%. The business had revenue of $114.60 million for the quarter, compared to analyst estimates of $112.39 million. During the same quarter last year, the firm posted $0.22 earnings per share. The business’s revenue was up 16.8% compared to the same quarter last year. Equities analysts expect that Medidata Solutions will post $1.01 EPS for the current year.
In other Medidata Solutions news, Vice Chairman Steven Isaac Hirschfeld sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, July 12th. The stock was sold at an average price of $49.85, for a total value of $498,500.00. Following the completion of the sale, the insider now owns 110,400 shares of the company’s stock, valued at $5,503,440. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Eileen Schloss sold 2,083 shares of the firm’s stock in a transaction dated Friday, July 29th. The stock was sold at an average price of $53.04, for a total value of $110,482.32. Following the completion of the sale, the executive vice president now directly owns 29,013 shares of the company’s stock, valued at approximately $1,538,849.52. The disclosure for this sale can be found here. Corporate insiders own 6.70% of the company’s stock.
A number of large investors have recently modified their holdings of MDSO. LS Investment Advisors LLC increased its stake in shares of Medidata Solutions by 9.2% in the second quarter. LS Investment Advisors LLC now owns 2,411 shares of the company’s stock valued at $113,000 after buying an additional 203 shares in the last quarter. BlackRock Inc. increased its stake in shares of Medidata Solutions by 127.8% in the first quarter. BlackRock Inc. now owns 3,690 shares of the company’s stock valued at $143,000 after buying an additional 2,070 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Medidata Solutions by 5.3% in the second quarter. Tower Research Capital LLC TRC now owns 3,498 shares of the company’s stock valued at $164,000 after buying an additional 177 shares in the last quarter. Parkwood LLC acquired a new stake in shares of Medidata Solutions during the second quarter valued at $200,000. Finally, Shelton Capital Management acquired a new stake in shares of Medidata Solutions during the second quarter valued at $218,000.
Medidata Solutions Company Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Medidata Clinical Cloud provides a platform of technology and data analytics solutions designed to manage activities across clinical development.
Receive News & Stock Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related stocks with our FREE daily email newsletter.